Atopic Dermatitis

Prior to the study, little was known on the relationship between the disease and fractures.

Investigators suggested systemic mental health monitoring could be beneficial for women who have atopic disease before pregnancy.

Investigators called for more studies which feature adequately powered trials of test-guided dietary exclusions.

The topical drug was associated with adverse events that were mainly localized to the application site and mild to moderate in nature.

The condition is rare, with limited epidemiological data and no standard treatment.

Significant 2-way interactions were found of atopic dermatitis with sleep disturbance as predictors of ≥75th percentile for poor task completion at 9 years of age.

Investigators called for prospective studies with longer time horizons to see if these associations persist throughout childhood.

Closing out its discussion on atopic dermatitis, the panel considers best practices and unmet needs in the treatment landscape.

A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.

Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.

Though not all hemangioma last past 10 years old in pediatric patients, some untreated hemangioma are associated with high risk of ulceration.

Dr. Swanson also details the effects of the COVID-19 pandemic on her practice with the implementation of telemedicine.

Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.

Shared insight on the armamentarium of systemic agents available to treat atopic dermatitis.

A review of topical therapies that have been long utilized for patients with atopic dermatitis.

Year-long treatment with the biologic resulted in significant improvements in patient perception of well-being and treatment effect.

Investigators reported that the medication was safe for patients with moderate-to-severe atopic dermatitis regardless of the presence of allergic comorbidities.

Investigators collected data from 5 focus groups of community-based pediatricians to address ongoing concerns on the treatment of atopic dermatitis in this pediatric population.

Data from the LIBERTY AD ADOL trial showed that adolescent patients with moderate-to-severe atopic dermatitis treated with the biologic reported decreases in total and allergen-specific IgE levels for cat dander, peanuts, and more.

Over half of all patients in the study had achieved an EASI-75 within a year, and investigators noted that patient and family satisfaction with the MADP program was high.

Investigators report that the skin condition mediated the association between a a interleukin-4 receptor agonist variant and food allergy.

Investigators report that 21.9% of all participants with allergic contact dermatitis had 1 or more currently relevant reactions to a supplemental allergen/substance.

A brief review of patient and disease factors that inform selection of therapy for atopic dermatitis.

Expert insight on nonpharmacological strategies to treat atopic dermatitis and improve patient quality of life.

By identifying 22 key parameters in study designs, investigators hope to establish a standardized approach for analyzing moderate-to-severe atopic dermatitis trial results.